The global cancer burden attributable to these infectious agents was about 2 million cases in 2008. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, December 27, 2015 /EINPresswire.com/ --


“Infected with the Epstein Barr Virus (EBV)? The CBCD recommends taking Novirin or Gene-Eden-VIR.” – Greg Bennett, CBCD

A study examined rates of cancer in Australia caused by the Epstein-Barr Virus (EBV) among six other viruses. These other viruses included: (human papillomavirus [HPV], hepatitis B virus [HBV], hepatitis C virus [HCV], human immunodeficiency virus, type 1 [HIV-1], Kaposi's sarcoma herpes virus [KSHV] and human T-cell lymphotrophic virus, type-1 [HTLV-1]). (1)

Specifically in regards to EBV infection and cancer, the last date for which accurate data is available was 2010. According to Dr. Antonsson and colleagues, “we estimate 107 NPC ( nasopharyngeal carcinoma) in Australian in 2010 were caused by EBV … we estimated 188 of the 572 cases of Hodgkin's lymphoma that occurred in Australia in 2010 could be attributed to EBV infection (33% of all Hodgkin's lymphoma cases) … (and) … virological surveys indicate that 15-30% of the non-endemic Burkitt's lymphoma occurring in western populations is caused by EBV.” (1)

Click to learn more about EBV symptoms.

The CDC notes that “Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives.” (2) The Center for the Biology of Chronic Disease (CBCD) recommends that in light of the medical evidence, infected individuals in Australia take Novirin or Gene-Eden-VIR. The formula of these natural, antiviral supplements was designed to help the immune system target the latent EBV.

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the herpes family of viruses. The Epstein Barr Virus (EBV) is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the EBV … reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3) The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

http://www.gene-eden-vir.com

and

http://www.novirin.com

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Some doctors argue that latent viruses are inactive, that is, they show no transcription (production of proteins) and no shedding. Since the virus is inactive it is harmless. In contrast, Dr. Tikhmyanova wrote that “Epstein-Barr Virus (EBV) persists as a latent infection in many lymphoid and epithelial malignancies, including Burkitt's lymphomas, nasopharyngeal carcinomas, and gastric carcinomas. Current chemotherapeutic treatments of EBV-positive cancers include broad-spectrum cytotoxic drugs that ignore the EBV-positive status of tumors.” (4)

The evidence is building that latent viruses are active, although on a reduced scale, and are still dangerous. A paper entitled “Human Cytomegalovirus Persistence” published February 13, 2012 in the journal Cellular Microbiology, clearly says that latent viruses are active. “Both the chronic and latent states of infection contribute to HCMV persistence and to the high HCMV seroprevalence worldwide. The chronic infection is poorly defined molecularly, but clinically manifests as low-level virus shedding over extended periods of time and often in the absence of symptoms.” (5) To clarify, the expression “absence of symptoms” means the absence of standard symptoms, which are usually associated with active infection. Also note how the paper describes viral shedding during latency.

“The results of these studies are consistent with the research conducted by the CBCD on Microcompetition and the clinical studies on the formula of Novirin and Gene-Eden-VIR.” - Greg Bennett, CBCD

References:

(1) Antonsson A1, Wilson LF1, Kendall BJ1,2, Bain CJ1,3, Whiteman DC1,4, Neale RE1,4. "Cancers in Australia in 2010 attributable to infectious agents." Aust N Z J Public Health. 2015 Oct;39(5):446-51.

(2) CDC.gov - About Epstein-Barr Virus (EBV). Last updated January 6, 2014. http://www.cdc.gov/epstein-barr/about-ebv.html

(3) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

(4) Tikhmyanova N1, Schultz DC, Lee T, Salvino JM, Lieberman PM. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus. ACS Chem Biol. 2014 Mar 21;9(3):785-95.
http://www.ncbi.nlm.nih.gov/pubmed/24028149

(6) Felicia Goodrum,1,2,3 Katie Caviness,3, and Patricia Zagallo1, Human Cytomegalovirus Persistence, Cell Microbiology. Published May 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330195/#__ffn_sectitle

Greg Bennett
CBCD
585-250-9999
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.